Page 3 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

Pertuzumab-trastuzumab fixed-dose combination

for subcutaneous (SC) injection

1. HER2 POSITIVE DISEASE BURDEN

1.1. Epidemiology of breast cancer (BC)

Global prevalence 1

BC is the It is a leading Estimated Global
most frequently cause of cancer number of new BC deaths
diagnosed related deaths BC cases approximately
cancer in women 2.08 million in 626,679
worldwide 2018 (25% of all
cancers in women)

Prevalence of HER2-positive BC in the population 2,3
15–20% 23.5% of BC in

of primary BC the Asian population

HER2-positive BC mortality rate according to Surveillance, Epidemiology,
and End Results Program (SEER) data 2015 4-6

78,000–104,000 deaths per year globally 4-6

1.2. Disease burden of BC

Impact of BC on patients
 Compared to the general population, patients with BC experience:

Reduced
health Fatigue 9-13 Sexual
related dysfunction 9-13 Infertility 9-13 Stress 11,14 Mental
quality disorders 11,14
of life
(HRQoL) 7,8

M-AE-00000086 3